Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the…
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative…